Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Kai Donsbach"'
Autor:
Vijayagopal Gopalsamuthiram, Dang Binh Ho, Cheryl L. Peck, Vasudevan Natarajan, Toolika Agrawal, Justina M. Burns, John Bachert, Daniel W. Cook, Rodger W. Stringham, Ryan Nelson, Saeed Ahmad, B. Frank Gupton, David R. Snead, D. Tyler McQuade, Rajappa Vaidyanathan, Kai Donsbach, Joshua D. Sieber
Publikováno v:
ACS Omega, Vol 7, Iss 8, Pp 7223-7228 (2022)
Externí odkaz:
https://doaj.org/article/5891606ae57846d2920a0e4a94cd083d
Publikováno v:
Catalysts, Vol 11, Iss 11, p 1287 (2021)
The active pharmaceutical ingredient levetiracetam has anticonvulsant properties and is used to treat epilepsies. Herein, we describe the enantioselective preparation of the levetiracetam precursor 2-(pyrrolidine-1-yl)butanamide by enzymatic dynamic
Externí odkaz:
https://doaj.org/article/806021d901a34b0cb1bbf25b458befe4
Autor:
Birgit Grill, Maximilian Glänzer, Helmut Schwab, Kerstin Steiner, Daniel Pienaar, Dean Brady, Kai Donsbach, Margit Winkler
Publikováno v:
Molecules, Vol 25, Iss 11, p 2521 (2020)
Nitrile hydratases (NHase) catalyze the hydration of nitriles to the corresponding amides. We report on the heterologous expression of various nitrile hydratases. Some of these enzymes have been investigated by others and us before, but sixteen targe
Externí odkaz:
https://doaj.org/article/3a759537ed4c491084b2d8b1d422c684
Publikováno v:
Organic Process Research & Development. 26:2564-2613
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a75b68b10160ac58573665d89ae8aab0
https://doi.org/10.1021/acs.oprd.2c00161
https://doi.org/10.1021/acs.oprd.2c00161
Autor:
Siegfried R. Waldvogel, Till Opatz, Georg Steinkellner, Margit Winkler, Helmut Schwab, Karl Gruber, Alexander M. Nauth, Urska Pogorevcnik, Birgit Grill, Kai Donsbach, Sebastian Arndt, Dominik Weis
Publikováno v:
Green Chemistry. 23:388-395
Levetiracetam is an active pharmaceutical ingredient widely used to treat epilepsy. We describe a new synthesis of levetiracetam by a dynamic kinetic resolution and a ruthenium-catalysed ex-cell anodic oxidation. For the enzymatic resolution, we tail
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c63ec24187129a1c188f3718b025a1f1
https://doi.org/10.1039/d0gc03358h
https://doi.org/10.1039/d0gc03358h
Publikováno v:
Nachrichten aus der Chemie. 68:26-29
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::502f91579ada191faa308b4ac7018018
https://doi.org/10.1002/nadc.20204100914
https://doi.org/10.1002/nadc.20204100914
Publikováno v:
Angewandte Chemie. 132:8112-8118
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::794399b158ff23bad3b12d6de397002c
https://doi.org/10.1002/ange.202002717
https://doi.org/10.1002/ange.202002717
Autor:
Vijayagopal, Gopalsamuthiram, Dang Binh, Ho, Cheryl L, Peck, Vasudevan, Natarajan, Toolika, Agrawal, Justina M, Burns, John, Bachert, Daniel W, Cook, Rodger W, Stringham, Ryan, Nelson, Saeed, Ahmad, B Frank, Gupton, David R, Snead, D Tyler, McQuade, Rajappa, Vaidyanathan, Kai, Donsbach, Joshua D, Sieber
Publikováno v:
ACS omega. 7(8)
A concise and practical synthesis has been developed to provide the 8-fluoro-5-hydroxy-3,4-diydrocarbostyril (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e7e50b041ef88a76afd4e7ab3d3b86a9
https://pubmed.ncbi.nlm.nih.gov/35252712
https://pubmed.ncbi.nlm.nih.gov/35252712
Publikováno v:
Catalysts, Vol 11, Iss 1287, p 1287 (2021)
Catalysts
Volume 11
Issue 11
Catalysts
Volume 11
Issue 11
The active pharmaceutical ingredient levetiracetam has anticonvulsant properties and is used to treat epilepsies. Herein, we describe the enantioselective preparation of the levetiracetam precursor 2-(pyrrolidine-1-yl)butanamide by enzymatic dynamic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15321fcc58dc6aa6550439aa8dd99099
https://www.mdpi.com/2073-4344/11/11/1287
https://www.mdpi.com/2073-4344/11/11/1287
Publikováno v:
The Journal of Organic Chemistry. 84:4856-4866
Ozanimod represents a recently developed, promising active pharmaceutical ingredient (API) molecule in combating multiple sclerosis. Addressing the goal of a scalable, economically attractive, and technically feasible process for the manufacture of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0257d1ce8d7f32c8cf3c8815e8346bf
https://doi.org/10.1021/acs.joc.8b03290
https://doi.org/10.1021/acs.joc.8b03290